Industry Newsclinical trialsbiopharmacardiovascularanalyst ratings
Kiniksa Advances Phase 2 Study, Analysts Raise Targets
5.0
Kiniksa Pharmaceuticals on Dec. 17 updated progress on its Phase 2 KPL-387 monotherapy study aimed at transitioning recurrent pericarditis patients from existing therapies, featuring a 16-week primary period and a 24-month extension. Earlier, Wells Fargo on Dec. 12 assigned a Buy with a $45 target; as of Dec. 19 all six covering analysts give Buy ratings, with a $52.83 consensus one-year price target (22.3% upside).
Key Points
- 1Announces Phase 2 KPL-387 monotherapy study with 16-week primary period and 24-month long-term extension
- 2Highlights potential pipeline value uplift if KPL-387 safely replaces existing therapies for recurrent pericarditis
- 3Shows unanimous analyst optimism: six Buy ratings and $52.83 consensus target implying 22.3% one-year upside
Scoring Rationale
Official management updates and consensus analyst targets increase credibility, but biotech focus limits broader AI/ML relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
